NCT06085625 is a Phase 2 clinical trial of Pre-Surgery Survey in Thyroid Lobectomy, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT06085625?

NCT06085625 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT06085625?

Interventions in NCT06085625: Pre-Surgery Survey, Post-Surgery Surveys.

What condition does NCT06085625 study?

NCT06085625 studies Thyroid Lobectomy.

Is NCT06085625 still recruiting?

NCT06085625 is currently recruiting now. Last updated 13 November 2025.

Last reviewed 2025-11-13 · How we verify

NCT06085625

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized Control Trial for Patient Reported Outcomes and Safety in Outpatient Thyroid Lobectomy

Recruiting now Phase 2 Last updated 13 November 2025

What this trial tests

Phase 2 trial testing Pre-Surgery Survey in Thyroid Lobectomy in 224 participants. Currently enrolling.

Timeline

26 November 2024

Primary endpoint
1 November 2027

1 November 2027

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	224
Start date	26 November 2024
Primary completion	1 November 2027
Estimated completion	1 November 2027
Sites	1 location across United States

Drugs / interventions tested

Pre-Surgery Survey
Post-Surgery Surveys

Conditions studied

Thyroid Lobectomy — all drugs for Thyroid Lobectomy →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Thyroid Lobectomy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare same-day discharge and overnight (or longer) observation practices and learn more about the differences in patient preferences, safety outcomes, and economic and resource impact

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06085625 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 13 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06085625.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing